Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 426-840-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Delivery of Animals: December 02, 1996 - Termination: January 20, 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: Directive 92/69/EEC, B. 7. "Subacute Toxicity Oral"
- Version / remarks:
- July 31, 1992
- Qualifier:
- according to guideline
- Guideline:
- other: "Japanese Guidelines for Screening Toxicity Testing of Chemicals: Testing Methods for New Chemical Substances"
- Version / remarks:
- enacted July 13, 1974, amended December 5,1986
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Hanlbm:WIST (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BRL, Biological Research Laboratories Ltd. Wolferstrasse 4 4414 Fuellinsdorf/Switzerland
- Age at study initiation (at delivery): 6 weeks
- Weight at study initiation: At acclimatization: Males: 127-176 grams (mean 150 grams); Females: 98-130 grams (mean 114 grams)
- Housing: Groups of five in Makrolon type-4 cages with standard softwood bedding ('Lignocel' Schill AG , 4132 Muttenz /Switzerland).
- Diet (e.g. ad libitum): Pelleted standard Kl i ba no. 343 rat maintenance di et (KLIBA MUhl en AG, 4303 Kaiseraugst/Switzerland) was available ad libitum (Batch no. 81/96) . The feed batch was analyzed for contaminants.
- Water (e.g. ad libitum): Tap water was available ad libitum in water bottles. Results of bacteriological assays, chemical and contaminant analysis of representative samples are attached to this report
- Acclimatization: 7 days under test conditions following a health examination. Only animals without any visible signs of illness were used for the study.
DETAILS OF FOOD AND WATER QUALITY: None of the contaminants analysed in the water and diet is considered to have been present at a concentration which would have affected the validity of the results.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3
- Humidity (%): 40-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12, (light period between 6.00 a.m. and 6.00 p.m.), music during the light period.
IN-LIFE DATES:
Allocation A (toxicity testing: termination after 28 treatment days) :
Allocation B (recovery testing: termination after an additional 14-day recovery period): - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- bi-distilled water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Frequency of preparation: daily, prior to each application
SCARLET RN 1165 was weighed into a glass beaker on a tared Mettler balance and the vehicle added. The mixtures were prepared using a magnetic stirrer.
Homogeneity of the test article in the vehicle was maintained during treatment using a magnetic stirrer.
VEHICLE
bi-distilled water - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability of the test article/vehicle mixtures were determined in samples taken during acclimatization and during week 3 of the treatment. The analyses were performed in the Analytical Laboratories of RCC Umweltchemie AG according to a method supplied by the sponsor (for results please refer to Attachment 4, pp. 219-233 of the study report).
Chemical analysis of dose preparations: at acclimatization 04-DEC-1996, at 3 weeks 24-DEC-1996 - Duration of treatment / exposure:
- Duration of acclimatization : 7 days
Duration of treatment : 28 days
Duration of recovery : 14 days - Frequency of treatment:
- Once daily
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5 for Allocation A - toxicity testing: termination after 28 treatment days
5 additional only for 0 (control) and 1000 mg/kg bw/day groups for Allocation B - recovery testing: termination after an additional 14-day recovery period - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based upon the results of a non-GLP 5-day dose- range-finding study (RCC Study Number 816028) in which BLUE GS 5664.80 was administered by gavage to 2 rats per group and sex.
- Rationale for dose level selection: Based upon data from an acute toxicity study (RCC Project 639685) and a 5-day dose-range-finding study (RCC Project 639742) in which SCARLET RN 1165 was administered by gavage to 3 rats per sex and dose group.
Between test days 3 to 5 the absolute and relative food consumption was statistically significantly higher in males treated at 1000 mg/kg when compared with the controls. As the food consumption of these animals was already higher during the pretest, no toxicological relevance was attributed to this findings.
- Post-exposure recovery period in satellite groups: 14 days - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: body weights were recorded weekly during pretest, weeks 1-3 and 5. Twice weekly in weeks 4 and 6.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Time schedule for examinations: The food consumption was recorded once during the pretest period and weekly thereafter using an on-line electronic recording system consisting of a Mettler balance connected to the RCC computer
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not specified
FOOD EFFICIENCY: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: at pretest 06-DEC-1996, at 4 weeks 03-JAN-1997 and at 6 weeks 17-JAN-1997
- Dose groups that were examined: Ophthalmologic findings were noted in a small proportion of animals from all groups. They included persistent pupillary membranes and corneal opacity. These findings occurred at similar incidences in the control and treated groups at the end of the treatment period. Therefore, they are considered to be unrelated to treatment with test article.
HEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks 06-JAN-1997 and after 6 weeks 20-JAN-1997, Blood samples were collected between the hours of 06.15 and 07.50 to reduce biological variation caused by circadian rhythms
- Anaesthetic used for blood collection: Yes- Blood samples for hematology and clinical biochemistry were collected from all animals under light ether anesthesia.
- Animals fasted: Yes -The animals were fasted in metabolic cages for approximately 18 hours before blood sampling but allowed access to water ad libitum
- How many animals: all animals
- Parameters checked: Erythrocyte count; Hemoglobin; Hematocrit; Mean corpuscular volume; Mean corpuscular hemoglobin; Mean corpuscular hemoglobin concentration; Platelet count; Reticulocyte count; Reticulocyte fluorescence ratios; Nucleated erythrocytes (normoblasts); Heinz bodies; Methemoglobin; Total leukocyte count; Differential leukocyte count; Red blood cell morphology; Thromboplastin time (=prothrombin time); Activated partial thromboplastin time. Please refer to pg. 20-21-22 of the study report for all parameters examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after 4 weeks 06-JAN-1997 and after 6 weeks 20-JAN-1997, Blood samples were collected between the hours of 06.15 and 07.50 to reduce biological variation caused by circadian rhythms
- Animals fasted: Yes -The animals were fasted in metabolic cages for approximately 18 hours before blood sampling but allowed access to water ad libitum
- How many animals: all animals
- Parameters checked: Glucose; Urea; Creatinine; Uric acid; Bilirubin, total; Cholesterol, total; Triglycerides; Phospholipids; Aspartate aminotransferase; Alanine aminotransferase; Lactate dehydrogenase
Creatine kinase; Alkaline phosphatase; Gamma-glutamyl transferase; Calcium; Phosphorus; Sodium; Potassium; Chloride; Albumin; Protein, total; Globulin; Albumin/Globulin ratio. Please refer to pg. 23-26 of the study report for all parameters examined.
URINALYSIS: Yes
- Time schedule for collection of urine: Urine was collected during the 18-hour fasting period into a specimen vital. Blood sampling : after 4 weeks 06-JAN-1997 and after 6 weeks 20-JAN-1997
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Yes -The animals were fasted in metabolic cages for approximately 18 hours before blood sampling but allowed access to water ad libitum
- Parameters checked: Volume (18-hour); Specific gravity; Osmolality; Color; Appearance; pH; Protein; Glucose; Ketone; Bilirubin; Blood; Nitrite; Urobilinogen; Urine sediment. Please refer to pg. 27-29 of the study report for all parameters examined.
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No
OTHER:
MORTALITY/VIABILITY: twice daily - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- All animals
- Necropsy after 4 weeks 06-JAN-1997; after 6 weeks 0-JAN-1997
- Tissus and organs collected:
Adrenal glands, aorta, bone - sternum and femur; bone marrow - femoral and sternal; brain, epididymides, esophagus, eyes with optic nerve and Harderian gland, heart, joint - femorotibial, kidneys, large intestine - cecum, colon and rectum; lacrimal glands - exorbital, larynx, liver, lungs, lymph nodes - mesenteric and mandibular; mammary gland area, nasal cavity, ovaries, pancreas, pituitary gland, prostate gland, salivary glands - mandibular and sublingual; sciatic nerve, seminal vesicles, skeletal muscle, skin, small intestine - duodenum, jejunum and ileum; spinal cord - cervical, midthoracic and lumbar segments; spleen, stomach, testes, thymus, thyroid glands with parathyroid glands, tongue, trachea, urinary bladder, uterus, vagina and all gross lesions.
ABSOLUTE AND RELATIVE ORGAN WEIGHTS: Yes
The following organ weights were recorded on the scheduled dates of necropsy: Adrenals, brain, heart, kidneys, liver, ovaries, pituitary, spleen, testes, thyroid including parathyroid gland.
The organ to terminal body weight ratios as well as the organ to brain weight ratios were determined.
The determination of the terminal body weight was performed immediately prior to necropsy.
HISTOPATHOLOGY: Yes
Slides of adrenals, heart, kidneys, liver, lungs, spleen, stomach and testes collected at terminal sacrifice from the animals of group 1 (control) and group 4 (high-dose) as well as the stomach and gross lesions from rats of all groups were examined by a pathologist. - Other examinations:
- DATA CALCULATION
FOOD CONSUMPTION
The food consumption was calculated per rat and per food consumption interval. It expresses the average food consumed per animal and per day over the food consumption interval.
FC = C/AD
where
FC is Food consumption in grams of food per animal and day;
C is measured food consumption in grams per cage over the consumption interval and AD is total consumption days over all animals in the cage during the consumption interval (the mortality during the consumption interval is therefore taken into account).
RELATIVE FOOD CONSUMPTION
The relative food consumption was calculated according to the following formula:
RFC = [FC/BW(i)]x1000
where
BW(i) is the most ideal body weight in grams or the body weight (of the corresponding rats) recorded on the day most close to the middle of the food consumption interval. In cases of equal "closeness" of two body weight records the later one was chosen;
RFC is relative food consumption in grams of food per kg body weight and day, and FC is food consumption in grams of food per animal and day (gram).
Unit is gram food per kg body weight and day - Statistics:
- The following statistical methods were used to analyze the body weights, organ weights all ratios as well as clinical laboratory data :
When the variables could be assumed to follow a normal distribution, the Dunnett-test (many to one t-test) based on a pooled variance estimate was applied for the comparison between the treated groups and the control groups for each sex.
The Steel-test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution.
The Fisher's exact test was applied to the ophthalmoscopy data and macroscopical findings.
References :
- C.W. Dunnett: A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. Stat. Assoc. 50, 1096-1121 (1955).
- R.G. Miller: Simultaneous Statistical Inference, Springer Verlag, New York (1981).
- R.A. Fisher: Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh (1950). - Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no clinical signs in group 2 (50 mg/kg) and in females of group 3 (200 mg/kg). Red feces were noted in males of group 3 (200 mg/kg). In all animals of group 4 (1000 mg/kg) red urine and red feces were recorded. The discoloration proved to be reversible during the recovery period, allowed to rats of group 4 (1000 mg/kg).
- Mortality:
- no mortality observed
- Description (incidence):
- All animals survived their assigned study period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No differences from controls of statistical or biological significance were noted.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no effect on food consumption.
Slightly lower food consumption was recorded in males of group 3 (200 mg/kg), only. In the absence of any effect on food consumption in rats of group 4 (1000 mg/kg), this difference from the control is considered to be incidental. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Ophthalmologic findings were noted in a small proportion of animals from all groups. They included persistent pupillary membranes and corneal opacity. These findings occurred at similar incidences in the control and treated groups at the end of the treatment period. Therefore, they are considered to be unrelated to treatment with test article.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Treatment period and Recovery period - no remarkable findings were noted.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Treatment period - Slightly decreased glucose level in females of group 4 (p<0.01), marginally increased creatinine level in males of group 4 (p<0.05), slightly increased uric acid level in both sexes of group 4 (p<0.01), slightly to markedly increased total bilirubin level in both sexes of groups 3 and 4 (p<0.05 - p<0.01), slightly increased triglyceride level in both sexes of group 4 (p<0.01), slightly decreased calcium level (p<0.01) and marginally increased chloride level (p<0.05) in females of group 4.
In addition, plasma discoloration was observed in all animals of groups 3 and 4, ranging from a light red in group 3 to red in group 4.
Recovery period - all findings recorded during the treatment period were found to be reversible and generally similar to those of the controls. However, a slightly but statistically significantly increased uric acid and total bilirubin level in males (p<0.05 - p<0.01), and slightly increased chloride level in females (p<0.05) were yet to be noted. Subsequently, no further plasma discoloration was observed. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Treatment period- Apart from urine discoloration, no remarkable findings were noted. Urine discoloration as observed in both sexes of groups 3 and 4 ranged from a deep-yellow (2 females) to light-orange (4 males) to orange (1 male) in
group 3 to orange (1 male, 8 females) to deep-orange (2 males, 1 female) to red (7 males, 1 female) in group 4. Moreover, a deep-yellow urine discoloration was also noted in 3 out of 5 males and 2 out of 5 females of group 2 ( 50 mg/kg).
Recovery period - Reversibility of the urine discoloration was observed, however, a deep-yellow discoloration was yet to be noted in all males and in two out of five females of the recovery group .
Due to the extreme test article-related discoloration of the plasma samples in groups 3 and 4, the biological relevance of the clinical biochemistry findings to the treatment remains doubtful. All other statistical differences in the results of the hematology, cltnical biochemistry or urinalysis parameters during the treatment or recovery period were considered to be incidental and unrelated to the treatment, and of normal biological variation for rats of this strain and age (for reference, refer to historical control data for untreated Wistar HanIbm rats, pp. 200-217 of the study report) - Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- The absolute and relative organ weights did not distinguish treated groups from controls.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Reddish discoloration was noted mainly in the disgestive tract and kidneys from primarily rats of group 4 and 3 at the end of the main study period. This was due to the test article, a dyestuff and was not accompanied by microscopic
alterations . - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Miscroscopic findings:
In rats of both sexes from group 4 at the end of the main study period, there was a slight increase in the incidence and severity compared to the controls, of minimal to slight degrees of apoptotic bodies in the parietal cells of the gastric mucosa. This alteration was accompanied by minimal degree of vacuolation of the squamous epithelium of the limiting ridge and a slight increase in the incidence and severity of minimal to slight inflammatory cell infiltration of the glandular submucosa.
These findings were also present to a lesser degree in group 3. At the end of the recovery period these findings had largely reversed to background levels .
The remainder of microscopic findings recorded were within the normal range of background morphologic alterations which may be recorded in this strain and age of Wistar rat and occurred at similar incidences and severity in both control and treated rats at both sacrifices. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Details on results:
- DISCUSSION OF THE RESULTS
The oral administration of SCARLET RN 1165 to Wistar rats at doses of 50, 200 and 1000 mg/kg/day, for 28 days, resulted in no effects on mortality, food consumption, body weight, ophthalmoscopic examinations and organ weights.
Treatment with test article , a pigment, resulted in red feces in males at 200 mg/kg. Red feces and red urine was observed in all animals at 1000 mg/kg.
Test article-related changes of clinical biochemistry and urinalysis comprised the following parameters: slightly decreased glucose level in females of group 4 (p<0.01), marginally increased creatinine level in males of group 4 (p<0.05), slightly increased uric acid level in both sexes of group 4 (p<0.01), slightly to markedly increased total bil i rubin level in both sexes of groups 3 and 4 (p<0.05 - p<0.01), slightly increased triglyceride level in both sexes of group 4 (p<0.01), slightly decreased calcium level (p<0.01) and marginally increased chloride level (p<0.05) in females of group 4.
Plasma discoloration and urine discoloration was observed in all animals of groups 3 and 4. Urine discoloration was also present in some animals of group 2 (50 mg/kg).
Recovery period - all of the findings recorded during the treatment period were found to be reversible and generally similar to those of the controls. However, for clinical biochemistry data a slightly, but statistically significantly increased uric acid and total bilirubin level in males (p<0.05 - p<0.01), and slightly increased chloride level in females (p<0.05) were yet to be noted.
Subsequently, no further plasma discoloration was observed, whereas urinalysis indicated a deep-yellow urine discoloration in all males and in two out of five females.
Reddish discoloration was noted mainly in the digestive tract and kidneys from primarily rats of group 4 and 3 at the end of the main study period. This was due to the test article, a dyestuff and was not accompanied by microscopic
alterations.
Morphologic alterations following the administration of the test article were present in the stomach. These took the form of minor degrees of apoptotic bodies in parietal cells accompanied by also minor degrees of vacuolation of limiting ridge epithelium and inflammatory cell infiltration of the glandular submucosa. These findings had largely reversed following the recovery period. Both sexes of group 4 (1000 mg/kg) were clearly affected, group 3 (200 mg/kg) to a lesser degree. These findings may be regarded as indicators of a slight irritant effect of the test article on the gastric mucosa.
Based on the results of this study, 50 mg/kg SCARLET RN 1165 was established as the no-observed-adverse-effect level (NOAEL). Under the conditions of this study a no-observed-effect-level (NOEL) could not be determined. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
- urinalysis
- Key result
- Critical effects observed:
- no
- Conclusions:
- Oral administration of SCARLET RN 1165 to Wistar rats at doses of 0, 50, 200 and 1000 mg/kg/day, performed according to OECD 407/method EC B7, for 28 days resulted in the following:
Based on the results of this study, 50 mg/kg SCARLET RN 1165 was established as the no-observed-adverse-effect level (NOAEL). - Executive summary:
GENERAL
In this subacute toxicity study, SCARLET RN 1165 was administered daily by oral gavage to SPF-bred Wistar rats of both sexes at dose levels of 0, 50, 200 and 1000 mg/kg body weight/day for a period of 28 days.
The study comprised 5 animals per group and sex which were sacrificed after 28 days of treatment. Additional 5 rats per sex and group were used at 0 and 1000 mg/kg. These animals were treated for 28 days and then allowed a 14-day treatment-free recovery period after which they were sacrificed.
Clinical signs, food consumption and body weights were recorded periodically during the acclimatization, treatment and recovery period. Ophthalmoscopic examinations were performed during acclimatization, at the end of the treatment and recovery period.
At the end of the dosing period and the treatment-free period, blood samples were withdrawn for hematology and plasma chemistry analyses, and urine samples were collected for urinalysis. All animals were killed, necropsied and examined post mortem. Samples of major organs from all group 1 (0 mg/kg) and group 4 (1000 mg/kg) animals, as well as stomach and gross lesions from all animals were processed as hematoxylin and eosin stained slides and examined by light microscopy.
The results of the study are summarized as follows:
MORTALITY
All animals survived their assigned study period.
CLINICAL SIGNS
There were no clinical signs in group 2 (50 mg/kg) and in females of group 3 (200 mg/kg). Red feces were noted in males of group 3 (200 mg/kg). In all animals of group 4 (1000 mg/kg) red urine and red feces were recorded. The discoloration proved to be reversible during the recovery period, allowed to rats of group 4 (1000 mg/kg).
BODY WEIGHT
There was no effect on body weight.
FOOD CONSUMPTION/RELATIVE FOOD CONSUMPTION
There were no effects on food consumption or relative food consumption.
OPHTHALMOSCOPIC EXAMINATIONS
There were no treatment-related changes on the ophthalmological findings.
HEMATOLOGY/CLINICAL BIOCHEMISTRY/ URINALYSIS
In the assessment of hematology, clinical biochemistry and urinalysis data the following changes recorded between the control and treated rats of groups 3 (200 mg/kg) and/or 4 (1000 mg/kg) at termination of the treatment were considered to be test article related:
Hematology - no remarkable findings were noted.
Clinical Biochemistry - slightly decreased glucose level in females of group 4 (p<0.01), marginally increased creatinine level in males of group 4 (p<0.05), slightly increased uric acid level in both sexes of group 4 (p<0.01), slightly to markedly increased total bilirubin level in both sexes of groups 3 and 4 (p<0.05 - p<0.01), slightly increased triglyceride level in both sexes of group 4 (p<0.01), slightly decreased calcium level (p<0.01) and marginally increased chloride level (p<0.05) in females of group 4.
In addition, plasma discoloration was observed in all animals of groups 3 and 4, ranging from a light red in group 3 to red in group 4.
Urinalysis - except for urine discoloration, no remarkable findings were noted.
Urine discoloration as observed in both sexes of groups 3 and 4 ranged from a deep-yellow (2 females) to light-orange (4 males) to orange (1 male) in group 3 to orange (1 male, 8 females) to deep-orange (2 males, 1 female) to red (7 males, 1 female) in group 4. Moreover, a deep-yellow urine discoloration was also noted in 3 out of 5 males and 2 out of 5 females of group 2 ( 50 mg/kg).
Recovery period - all of the findings recorded during the treatment period were found to be reversible and generally similar to those of the controls. However, for clinical biochemistry data a slightly, but statistically significantly increased uric acid and total bilirubin level in males (p<0.05 - p<0.01), and slightly increased chloride level in females (p<0.05) were yet to be noted.
Subsequently, no further plasma discoloration was observed, whereas urinalysis indicated a deep-yellow urine discoloration in all males and in two out of five females.
ORGAN WEIGHTS AND ORGAN WEIGHT RATIO
There were no treatment-related changes in organ weights and ratios.
MACROSCOPIC AND MICROSCOPIC FINDINGS
At the end of the dosage period, minor morphological alterations indicative of a slight irritant effect of the test article, were present in the gastric mucosa of rats of group 4 and to a lesser degree in group 3. These alterations took the form of minimal to slight degrees of apoptotic bodies in parietal cells accompanied by vacuolation of limiting ridge epithelium and inflammatory cell infiltration of the glandular submucosa. These findings had largely reversed following the recovery period.
DISCUSSION
The oral administration of SCARLET RN 1165 to Wistar rats at doses of 50, 200 and 1000 mg/kg/day, for 28 days, resulted in no effects on mortality, food consumption, body weight, ophthalmoscopic examinations and organ weights.
Treatment with test article , a pigment, resulted in red feces in males at 200 mg/kg. Red feces and red urine was observed in all animals at 1000 mg/kg.
Test article-related changes of clinical biochemistry and urinalysis comprised the following parameters: slightly decreased glucose level in females of group 4 (p<0.01), marginally increased creatinine level in males of group 4 (p<0.05), slightly increased uric acid level in both sexes of group 4 (p<0.01), slightly to markedly increased total bilirubin level in both sexes of groups 3 and 4 (p<0.05 - p<0.01), slightly increased triglyceride level in both sexes of group 4 (p<0.01), slightly decreased calcium level (p<0.01) and marginally increased chloride level (p<0.05) in females of group 4.
Plasma discoloration and urine discoloration was observed in all animals of groups 3 and 4. Urine discoloration was also present in some animals of group 2 (50 mg/kg)
Recovery period - all of the findings recorded during the treatment period were found to be reversible and generally similar to those of the controls. However, for clinical biochemistry data a slightly, but statistically significantly increased uric acid and total bilirubin level in males (p<0.05 - p<0.01), and slightly increased chloride level in females (p<0.05) were yet to be noted.
Subsequently, no further plasma discoloration was observed, whereas urinalysis indicated a deep-yellow urine discoloration in all males and in two out of five females.
Reddish discoloration was noted mainly in the digestive tract and kidneys from primarily rats of group 4 and 3 at the end of the main study period. This was due to the test article, a dyestuff and was not accompanied by microscopic alterations.
Morphologic alterations following the administration of the test article were present in the stomach.
These took the form of minor degrees of apoptotic bodies in parietal cells accompanied by also minor degrees of vacuolation of limiting ridge epithelium and inflammatory cell infiltration of the glandular submucosa. These findings had largely reversed following the recovery period. Both sexes of group 4 (1000 mg/kg) were clearly affected, group 3 (200 mg/kg) to a lesser degree. These findings may be regarded as indicators of a slight irritant effect of the test article on the gastric mucosa.
CONCLUSION
Oral administration of SCARLET RN 1165 to Wistar rats at doses of 0, 50, 200 and 1000 mg/kg/day, performed according to OECD 407/method EC B7, for 28 days resulted in the following:
Based on the results of this study, 50 mg/kg SCARLET RN 1165 was established as the no-observed-adverse-effect level (NOAEL).
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 50 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Klimish code 1 (OECD 407 & GLP)
- System:
- gastrointestinal tract
- Organ:
- other: gastric mucosa
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.